FIELD: pharmaceuticals.
SUBSTANCE: provided is a stable pharmaceutical composition for oral administration, containing 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazine-1-yl)piperidine-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to in this document as Compound A) or a pharmacologically acceptable salt thereof, wherein production of associated substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of Compound A or a pharmaceutically acceptable salt thereof is 60% or more relative to the total amount of Compound A or a pharmaceutically acceptable salt thereof.
EFFECT: production of a stable pharmaceutical composition for oral administration.
6 cl, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | 2010 |
|
RU2526253C2 |
| PYRAZOLO[3,4-b]PURIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION (VERSIONS), APPLICATION (VERSIONS), COMBINATION (VERSIONS) | 2003 |
|
RU2357967C2 |
| NEW CATECHOL DERIVATIVES OR THEIR SALT, METHODS OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2795227C2 |
| AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICINE | 2012 |
|
RU2600976C2 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
| PYRASOLE[3,4-b]PYRIDINE COMPOUNDS AND THEIR APPLICATION AS PHOSPHODIESTERASE INHIBITORS | 2003 |
|
RU2348633C2 |
| SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | 2012 |
|
RU2569635C9 |
| POLYMORPH FORM OF 4-{[4-({[4-(2,2,2-TRIFLUOROETHOXY)-1,2-BENZISOXAZOL-3-YL]OXY}METHYL)PIPERIDIN-1-YL]METHYL}-TETRAHYDRO-2H-PYRAN-4-CARBOXYLIC ACID | 2012 |
|
RU2616978C2 |
| AGONISTS OF 5-HT4-RECEPTORS FOR TREATING DEMENTIA | 2011 |
|
RU2569733C2 |
